Does Cosentyx Increase Cancer Risk?
Clinical trials and post-marketing data for Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, show no overall increased risk of new cancer with prolonged use up to 5 years.[1][2] Malignancy rates in trials were low (about 1% across 52-week studies) and comparable to placebo or other biologics like TNF inhibitors.[1]
What Do Long-Term Studies Show?
In extension trials like FUTURE 5 (up to 5 years), standardized incidence ratios for malignancy (excluding non-melanoma skin cancer) matched general population rates, with no signal for dose- or duration-related increase.[2][3] Real-world registries, such as the Psoriasis Longitudinal Assessment and Registry (PSOLAR), report similar findings for IL-17 inhibitors versus other therapies.[4]
Any Specific Cancer Concerns?
No unique cancers linked to Cosentyx, but non-melanoma skin cancers occurred slightly more in some psoriasis trials (1-2% incidence), consistent with the underlying disease rather than the drug.[1][5] Patients with prior malignancy history were excluded from trials, leaving limited data for that group. No evidence of promotion in immunosuppressed states beyond standard biologic risks.[2]
Regulatory Warnings and Monitoring
FDA and EMA labels note malignancies in 0.7% of Cosentyx patients across trials (vs. 0.5% placebo), but advise caution in active cancer or recent history.[1][6] No black-box warning for cancer; monitoring follows general biologic guidelines (e.g., annual skin checks for psoriasis patients). EMA requires ongoing safety updates through 2028.[6]
How Does It Compare to Other Biologics?
| Drug Class | Cancer Risk Signal in Long-Term Data |
|------------|-------------------------------------|
| Cosentyx (IL-17i) | None elevated[2] |
| TNF inhibitors (e.g., Humira) | Slight skin cancer increase; lymphoma rare[4] |
| IL-23 inhibitors (e.g., Tremfya) | Comparable low rates[3] |
| JAK inhibitors (e.g., Xeljanz) | Higher malignancy warnings[7] |
Cosentyx aligns with lower-risk biologics; meta-analyses confirm no class-wide IL-17 oncogenicity.[3]
Who Might Face Higher Risks?
Patients with heavy UV exposure, smoking history, or prior immunosuppression show no amplified Cosentyx signal, but disease factors (e.g., severe psoriasis) elevate baseline cancer odds 1.5-2x.[5] No pediatric data links it to cancer development.
[1]: FDA Cosentyx Label
[2]: Annals of Rheumatic Diseases, 2022 Secukinumab 5-Year Safety
[3]: JAMA Dermatology, 2021 Biologic Cancer Meta-Analysis
[4]: PSOLAR Registry Update, 2023
[5]: British Journal of Dermatology, 2020 Psoriasis Cancer Risk
[6]: EMA Cosentyx EPAR
[7]: FDA JAK Warnings, 2021